The amount excludes working capital and taxes, he said.
The four brands are the Z&D zinc supplement, the insomnia medication Pedicloryl, the antibiotic Pecef, and Ezinapi, which is used for diaper rash.
The four brands combined achieved sales of Rs 33 crore in the financial year ending March 31, 2022.
The four brands, focused on the country’s pediatric segment, had a total covered market size of Rs 1,800 crore, JB Pharma said, citing data from market research firm IQVIA.
“JB Pharma sees good growth potential in the acquired brands as they synergize with its pediatric segment and will help it significantly leverage the strength of its field strength,” JB Pharma said in a statement.
The company sought acquisitions in the domestic brand market.
He had invested Rs 1,000 crore to fund acquisitions of Sanzyme portfolio of probiotics and heart failure drug Azmarda from
JB Pharma, which is ranked 25th in India’s pharmaceutical market according to IQVIA data for the year ending March 2022, moved up eight ranks with five of its brands in the top 300, according to market research firm AIOCD. Its domestic formulations business grew 33.6% in FY22, compared to industry growth of 27.9%.